Trichomonas vaginalis vaginitis in obstetrics and gynecology practice: New concepts and controversies

Obstetrical and Gynecological Survey

Volumn 68, Issue 1, 2013, Pages 43-50

  Coleman, Jenell S ^a   Gaydos, Charlotte A ^b   Witter, Frank ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; POTASSIUM HYDROXIDE; TINIDAZOLE;

ANTIGEN DETECTION; DYSPAREUNIA; DYSURIA; FEVER; GENITAL TRACT INFECTION; HUMAN; IRRITABILITY; LOW BIRTH WEIGHT; LOWER ABDOMINAL PAIN; MICROSCOPY; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN INFECTION; PARASITE LOAD; PARASITE TRANSMISSION; PERINATAL MORBIDITY; PH; POLYMORPHONUCLEAR CELL; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURITY; RECOMMENDED DRUG DOSE; REVIEW; SALPINGITIS; SINGLE DRUG DOSE; TRICHOMONIASIS; URINARY TRACT INFECTION; UTERINE TUBE; VAGINA DISCHARGE; VAGINAL SECRETION;

ANTI-INFECTIVE AGENTS; COINFECTION; DIRECTIVE COUNSELING; FEMALE; HIV INFECTIONS; HUMANS; METRONIDAZOLE; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PELVIC INFLAMMATORY DISEASE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; REPRODUCTIVE HEALTH SERVICES; SEXUALLY TRANSMITTED DISEASES; TRICHOMONAS VAGINALIS; TRICHOMONAS VAGINITIS; UNITED STATES; WOMEN'S HEALTH;

EID: 84872858174     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e318279fb7d     Document Type: Review

References (57)

1. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR. 2010;59 (No. RR-12): 58-61.
2. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36:6-10.
3. Neglected parasitic infections in theUnitedStates. 2012. Available at: www.cdc.gov/parasites/npi.html. Accessed August 15, 2012.
4. Brady L,ReidRD. The treatment of Trichomonas vaginalis vaginitis with the Lactobacillus. Ann Surg. 1942;115:840-848.
5. Cotch MF, Pastorek JG 2nd, Nugent RP, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis. 1997;24:353-360.
6. Hughes JP, Baeten JM, Lingappa JR, et al. Determinants of per-coital-act HIV-1 infectivity among African HIV-1Y serodiscordant couples. J Infect Dis. 2012;205:358-365.
7. Keith LG, Friberg J, Fullan N, et al. The possible role of Trichomonas vaginalis as a "vector" for the spread of other pathogens. Int J Fertil. 1986;31:272-277.
8. McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis. 2007;195:698-702.
9. Van Der Pol B, Kwok C, Pierre-Louis B, et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis. 2008;197:548-554.
10. Donné A. Animacules observes dans les matires purulent et le producit de secretion des organes genitaux de l'homme et de la femme. C R Acad Sci. 1836;3:385.
11. Nielsen TJ, Pradhan P, Brittingham A, et al. Glycogen accumulation and degradation by the trichomonads Trichomonas vaginalis and Trichomonas tenax. J Eukaryot Microbiol. 2012;59:359-366.
12. Khoshnan A, Alderete JF. Trichomonas vaginalis with a doublestranded RNA virus has upregulated levels of phenotypically variable immunogen mRNA. J Virol. 1994;68:4035-4038.
13. Draper D, Donohoe W, Mortimer L, et al. Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor. J Infect Dis. 1998;178:815-819.
14. Carlton JM, Hirt RP, Silva JC, et al. Draft genome sequence of the sexually transmitted pathogen Trichomonas vaginalis. Science. 2007;315:207-212.
15. ConradMD, GormanAW, Schillinger JA, et al. Extensive genetic diversity, unique population structure and evidence of genetic exchange in the sexually transmitted parasite Trichomonas vaginalis. PLoS Negl Trop Dis. 2012;6:e1573.
16. Goodman RP, Freret TS, Kula T, et al. Clinical isolates of Trichomonas vaginalis concurrently infected by strains of up to four Trichomonasvirus species (family Totiviridae). J Virol. 2011;85:4258-4270.
17. Minkoff H, Grunebaum AN, Schwarz RH, et al. Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. Am J Obstet Gynecol. 1984;150:965-972.
18. Schoonmaker JN, Lawellin DW, Lunt B, et al. Bacteria and inflammatory cells reduce chorioamniotic membrane integrity and tensile strength. Obstet Gynecol. 1989;74:590-596.
19. Draper D, Jones W, Heine RP, et al. Trichomonas vaginalis weakens human amniochorion in an in vitro model of premature membrane rupture. Infect Dis Obstet Gynecol. 1995;2:267-274.
20. Draper D, McGregor J, Hall J, et al. Elevated protease activities in human amnion and chorion correlate with preterm premature rupture of membranes. Am J Obstet Gynecol. 1995;173: 1506-1512.
21. Carey JC, Yaffe SJ, Catz C. The Vaginal Infections and Prematurity Study: an overview. Clin Obstet Gynecol. 1993;36: 809-820.
22. Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med. 2001;345:487-493.
23. al-Salihi FL,Curran JP,Wang J. Neonatal Trichomonas vaginalis: report of three cases and review of the literature. Pediatrics. 1974;53:196-200.
24. Smith LM, Wang M, Zangwill K, et al. Trichomonas vaginalis infection in a premature newborn. J Perinatol. 2002;22:502-503.
25. Trussell RE. Vaginal trichomoniasis, complement fixation, puerperal morbidity and early infection of the newborn infants. Am J Obstet Gynecol. 1942;44:292.
26. Fichorova RN. Impact of T. vaginalis infection on innate immune responses and reproductive outcome. J Reprod Immunol. 2009;83:185-189.
27. Guenthner PC, Secor WE, Dezzutti CS. Trichomonas vaginalisYinduced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. Infect Immun. 2005;73:4155-4160.
28. Petrin D, Delgaty K, Bhatt R, et al. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev. 1998;11: 300-317.
29. Laga M, Alary M, Nzila N, et al. Condom promotion, sexually transmitted diseases treatment, and declining incidence of HIV-1 infection in femaleZairian sexworkers. Lancet. 1994;344:246-248.
30. Hardy PH, Hardy JB, Nell EE, et al. Prevalence of six sexually transmitted disease agents among pregnant inner-city adolescents and pregnancy outcome. Lancet. 1984;2:333-337.
31. Mardh PA, Westrom L. Tubal and cervical cultures in acute salpingitis with special reference to Mycoplasma hominis and T-strain mycoplasmas. Br J Venereol Dis. 1970;46:179-186.
32. Reighard SD, Sweet RL, Vicetti Miguel C, et al. Endometrial leukocyte subpopulations associated with Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis genital tract infection. Am J Obstet Gynecol. 2011;205:324, e1-e7.
33. Francioli P, Shio H, Roberts RB, et al. Phagocytosis and killing of Neisseria gonorrhoeae by Trichomonas vaginalis. J Infect Dis. 1983;147:87-94.
34. Pindak FF, Mora de Pindak M, Hyde BM, et al. Acquisition and retention of viruses by Trichomonas vaginalis. Genitourin Med. 1989;65:366-371.
35. Scholtyseck E, Teras J, Kasakova I, et al. Electron microscope observations on the interaction of Mycoplasma fermentans with Trichomonas vaginalis. Z Parasitenkd. 1985;71:435-442.
36. Keith LG, Berger GS, Edelman DA, et al. On the causation of pelvic inflammatory disease. Am J Obstet Gynecol. 1984; 149:215-224.
37. Hobbs MM, Lapple DM, Lawing LF, et al. Methods for detection of Trichomonas vaginalis in the male partners of infected women: implications for control of trichomoniasis. J Clin Microbiol. 2006;44:3994-3999.
38. Kellock D, O'Mahony CP. Sexually acquired metronidazoleresistant trichomoniasis in a lesbian couple. Genitourin Med. 1996;72:60-61.
39. Hesseltine H, Wolters S, Campbell A. Experimental human vaginal trichomoniasis. J Infect Dis. 1942;71:127-130.
40. Weston TE, Nicol CS. Natural history of trichomonal infection in males. Br J Venereol Dis. 1963;39:251-257.
41. Wolner-Hanssen P, Krieger JN, Stevens CE, et al. Clinical manifestations of vaginal trichomoniasis. JAMA. 1989;261: 571-576.
42. Suriyanon V, Nelson KE, Choomsai na Ayudhya V. Trichomonas vaginalis in a perinephric abscess. A case report.AmJ TropMed Hyg. 1975;24:776-780.
43. Kingston MA, Bansal D, Carlin EM. 'Shelf life' of Trichomonas vaginalis. Int J STD AIDS. 2003;14:28-29.
44. Huppert JS, Mortensen JE, Reed JL, et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis. 2007;45:194-198.
45. Schwebke JR, Hobbs MM, Taylor SN, et al. Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial. J Clin Microbiol. 2011;49:4106-4111.
46. Hardick A, Hardick J, Wood BJ, et al. Comparison between the Gen-Probe transcription-mediated amplification Trichomonas vaginalis research assay and real-time PCR for Trichomonas vaginalis detection using a Roche LightCycler instrument with female self-obtained vaginal swab samples and male urine samples. J Clin Microbiol. 2006;44:4197-4199.
47. Nye MB, Schwebke JR, Body BA. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol. 2009;200:188.e1-188.e7.
48. Wood BA, Monro AM. Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses. Br J Venereol Dis. 1975;51:51-53.
49. Lossick JG, Muller M, Gorrell TE. In vitro drug susceptibility and doses of metronidazole required for cure in cases of refractory vaginal trichomoniasis. J Infect Dis. 1986;153:948-955.
50. Schmid G, Narcisi E, Mosure D, et al. Prevalence of metronidazole- resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med. 2001;46:545-549.
51. Cantu JM, Garcia-Cruz D. Midline facial defect as a teratogenic effect of metronidazole. Birth Defects Orig Artic Ser. 1982; 18:85-88.
52. Greenberg F. Possible metronidazole teratogenicity and clefting. Am J Med Genet. 1985;22:825.
53. Burtin P, Taddio A, Ariburnu O, et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol. 1995;172: 525-529.
54. Peterman TA, Tian LH, Metcalf CA, et al. High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: a case for rescreening. Ann Intern Med. 2006;145:564-572.
55. Ginocchio CC, Chapin K, Smith JS, et al. Prevalence of Trichomonas vaginalis and coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as determined by the APTIMA Trichomonas vaginalis nucleic acid amplification assay. J Clin Microbiol. 2012;50:2601-2608.
56. American Academy of Pediatrics and American College of Obstetricians and Gynecologists. Guidelines for Perinatal Care. 6th ed. Elk Grove Village, IL:AAP and ACOG; 2007.
57. Andrea SB, Chapin KC. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification assay and BD Affirm VPIII for detection of T. vaginalis in symptomatic women: performance parameters and epidemiological implications. J Clin Microbiol. 2011;49:866-869.